Capital Research Global Investors Portfolio holdings
Capital Research Global Investors (CRGI), a division of Capital Group established in 1931 and headquartered in Los Angeles, California, is a powerhouse in active investment management, overseeing hundreds of billions in assets with a focus on global equity portfolios. Known for its long-term, research-intensive approach, CRGI employs a unique multiple-portfolio-manager system to diversify risk and enhance returns, serving institutional clients, financial advisors, and individual investors through vehicles like the American Funds mutual fund family. The firm’s investment philosophy emphasizes fundamental analysis and a deep understanding of companies worldwide, aiming to identify growth opportunities over extended horizons. As part of Capital Group’s broader mission, CRGI has built a reputation for delivering consistent, value-driven results in the global investment landscape.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sea Limited
SE
|
+$1.96B |
| 2 |
AbbVie
ABBV
|
+$1.42B |
| 3 |
D.R. Horton
DHI
|
+$783M |
| 4 |
Amazon
AMZN
|
+$603M |
| 5 |
Eli Lilly
LLY
|
+$586M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Canadian Natural Resources
CNQ
|
+$1.18B |
| 2 |
EOG Resources
EOG
|
+$999M |
| 3 |
JPMorgan Chase
JPM
|
+$874M |
| 4 |
Comcast
CMCSA
|
+$746M |
| 5 |
TC Energy
TRP
|
+$626M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.11% |
| 2 | Healthcare | 16.91% |
| 3 | Consumer Discretionary | 13.72% |
| 4 | Industrials | 10.84% |
| 5 | Financials | 8.79% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AZUL
301
DELISTED
Azul
AZUL
| $62.5M | 0.02% |
7,677,917
-401,480
| -5% | -$3.38M |
|
302
PagSeguro Digital
PAGS
$2.4B
| $61.6M | 0.02% |
4,656,737
-9,194,141
| -66% | -$123M |
|
303
Leslie's
LESL
$12.4M
| $59.3M | 0.02% |
201,708
-148,764
| -42% | -$44.7M |
|
304
PPG Industries
PPG
$25.5B
| $59M | 0.02% |
+532,786
| New | +$65.8M |
|
|
AVDX
305
DELISTED
AvidXchange
AVDX
| $59M | 0.02% |
7,001,882
-3,681,397
| -34% | -$28.5M |
|
306
Saia
SAIA
$9.73B
| $58.2M | 0.02% |
306,161
+64,584
| +27% | +$13.7M |
|
307
Silicon Laboratories
SLAB
$7.3B
| $57.3M | 0.02% |
464,000
+45,000
| +11% | +$6.02M |
|
308
Alexandria Real Estate Equities
ARE
$8.27B
| $56.2M | 0.02% |
400,753
+327
| +0.1% | +$50.2K |
|
309
Edwards Lifesciences
EW
$53.6B
| $55.4M | 0.02% |
670,407
+245
| +0% | +$23.6K |
|
310
Newmont
NEM
$124B
| $52.5M | 0.02% |
1,250,000
+550,000
| +79% | +$25.7M |
|
|
CVT
311
DELISTED
Cvent Holding Corp. Common Stock
CVT
| $52.5M | 0.02% |
10,000,000
| – | – |
|
312
New York Times
NYT
$10.3B
| $52.2M | 0.02% |
1,814,638
| – | – |
|
313
Adobe
ADBE
$103B
| $52M | 0.02% |
188,800
-1,375,364
| -88% | -$520M |
|
314
Sempra
SRE
$56.2B
| $51.6M | 0.02% |
+688,328
| New | +$55.7M |
|
315
GSK
GSK
$101B
| $51.5M | 0.02% |
1,750,266
-2,703,892
| -61% | -$102M |
|
|
LTHM
316
DELISTED
Livent Corporation
LTHM
| $50.9M | 0.02% |
+1,660,893
| New | +$46.6M |
|
317
Bristol-Myers Squibb
BMY
$130B
| $50.4M | 0.02% |
709,449
| – | – |
|
|
AZPN
318
DELISTED
Aspen Technology Inc
AZPN
| $50.4M | 0.02% |
211,701
| – | – |
|
|
FISV
319
Fiserv Inc
FISV
$27.4B
| $50.2M | 0.02% |
536,700
| – | – |
|
320
Emerson Electric
EMR
$91.4B
| $50.1M | 0.02% |
683,618
-364
| -0.1% | -$30.2K |
|
|
GTM
321
ZoomInfo Technologies
GTM
$1.12B
| $48.8M | 0.02% |
1,170,312
-390,105
| -25% | -$16.6M |
|
322
Dow Inc
DOW
$22.1B
| $48.6M | 0.02% |
1,105,900
-1,068,941
| -49% | -$54.2M |
|
|
AEPPZ
323
DELISTED
American Electric Power Company, Inc. Corporate Units
AEPPZ
| $47.2M | 0.02% |
953,221
| – | – |
|
324
NCR Voyix
VYX
$1.12B
| $44.7M | 0.01% |
3,836,678
-318,600
| -8% | -$5.85M |
|
325
Brookfield Infrastructure
BIPC
$4.93B
| $43M | 0.01% |
1,056,214
+66,064
| +7% | +$3.04M |
|
Similar funds
Capital Research Global Investors's Q3 2022 Portfolio in Review
As of Q3 2022, Capital Research Global Investors held 452 positions worth $304B, down 5.2% from $321B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Capital Research Global Investors's Q3 2022 filing shows 29 new, 189 increased, 162 reduced and 23 closed positions. Its largest new stake was Centene: 2,829,733 shares worth $220M. The largest sale was Canadian Natural Resources, an estimated $1.18B.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 20% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Capital Research Global Investors's largest Q3 2022 buy was Centene: 2,829,733 shares worth $220M.
- Capital Research Global Investors added most to Sea Limited in Q3 2022, an estimated $1.96B increase.
- Capital Research Global Investors's biggest Q3 2022 reduction was Canadian Natural Resources, cutting an estimated $1.18B.
- Capital Research Global Investors fully exited Broadcom Inc. 8.00% Mandatory Convertible Preferred Stock, Series A in Q3 2022, selling an estimated $210M.
- Capital Research Global Investors's ten largest holdings make up 28% of its $304B portfolio in Q3 2022.
- Capital Research Global Investors opened 29 new positions and closed 23 in Q3 2022.
- Capital Research Global Investors's portfolio value fell 5.2% quarter-over-quarter to $304B.
Based on Capital Research Global Investors's 13F filing for Q3 2022, filed 14 Nov 2022.